Such a GRP78-affecting agent as nifetepimine (a dihydropyrimidone) was shown to manifest the antitumor properties in models of triple negative breast cancer (see Table 5 and refs [207,245]) and promote antitumor immune response by protecting CD4(+) T cells from tumor-induced apoptosis [246], but the potentially beneficial effect of nifetepimine on the immune response was not related to targeting tumoral GRP78. The gene discussed is HSPA5; the disease is triple-negative breast carcinoma.